Truxima is a biosimilar version of the brand-name drug Rituxan. Biosimilars tend to be less expensive than their brand-name versions. Doctors prescribe Truxima to treat conditions such as rheumatoid ...

Hyperthyroidism in Graves' ophthalmopathy results from B-cell-mediated production of autoantibodies against the TSH receptor (anti-TSHR antibodies), and levels of these autoantibodies correlate with ...

A trial evaluated whether rituximab can attain remission in adults with frequently relapsing nephrotic syndrome (FRNS) or steroid dependent nephrotic syndrome (SDNS).

Rituxan was administered at a dose of 1000 mg via IV infusion on day 1 and 15, with a repeat administration on days 168 and 182. MMF was administered at a dose of 2 grams orally daily from day 1 to ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the ...

Assessment of Tumor Size Reduction Improves Outcome Prediction of Positron Emission Tomography/Computed Tomography After Chemotherapy in Advanced-Stage Hodgkin Lymphoma Authors retain all rights in ...

In the case of Riabni according to Amgen, the list price in the U.S. will be 23.7% lower than Rituxan. Riabni will cost $716.80 per 100 mg and $3,584.00 per 500 mg single-dose vial at list price and ...

Updates from the annual ASH meeting, December 2018. The launch of biosimilar rituximab is an eagerly awaited event among US healthcare stakeholders who are cognizant of the high cost of intravenous ...

The patient was successfully treated with rituximab and intravenous immunoglobulin. Patients with flares of systemic lupus erythematosus (SLE), multiple organ involvement, and infections can pose a ...

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), said the FDA has granted priority review for Rituxan (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis ...

Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study. If you have the appropriate ...

—Rituxan is the first and only FDA-approved treatment for pediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis— “Rituxan is now approved ...